CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ --MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive ...
New research highlights a significant increase in postprandial glucose and insulin levels during the active phase of androgenic oral contraceptives, raising concerns about potential long-term ...
Metabolic diseases, including type 2 diabetes (T2D), obesity, and metabolic syndrome, are a growing threat to global public health. More than 537 million adults currently live with T2D, and this ...
Statistically Significant (p=0.006) Waist Circumference Reduction of 9.8 cm at Day 54 Significant Direct Hepatic Activity with a 23.7% Reduction in Liver Stiffness (VCTE) by Day 54 Strong Glycemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results